Gene therapy: therapeutic gene causing lymphoma
- PMID: 16641981
- DOI: 10.1038/4401123a
Gene therapy: therapeutic gene causing lymphoma
Abstract
The development of T-cell leukaemia following the otherwise successful treatment of three patients with X-linked severe combined immune deficiency (X-SCID) in gene-therapy trials using haematopoietic stem cells has led to a re-evaluation of this approach. Using a mouse model for gene therapy of X-SCID, we find that the corrective therapeutic gene IL2RG itself can act as a contributor to the genesis of T-cell lymphomas, with one-third of animals being affected. Gene-therapy trials for X-SCID, which have been based on the assumption that IL2RG is minimally oncogenic, may therefore pose some risk to patients.
Comment in
-
Gene therapy: X-SCID transgene leukaemogenicity.Nature. 2006 Sep 21;443(7109):E5-6; discussion E6-7. doi: 10.1038/nature05219. Nature. 2006. PMID: 16988659
-
Gene therapy: is IL2RG oncogenic in T-cell development?Nature. 2006 Sep 21;443(7109):E5; discussion E6-7. doi: 10.1038/nature05218. Nature. 2006. PMID: 16988660
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
